Early characterization of toxicity and efficacy would significantly impact the overall productivity of pharmaceutical R&D and reduce drug candidate attrition and failure. By describing the available platforms and weighing their relative advantages and disadvantages, including microarray data analysis, Genomics in Drug Discovery and Development introduces readers to the biomarker, pharmacogenomic, and toxicogenomics toolbox. The authors provide a valuable resource for pharmaceutical discovery scientists, preclinical drug safety department personnel, regulatory personnel, discovery toxicologists, and safety scientists, drug development professionals, and pharmaceutical scientists.
Format:
CONTRIBUTORS: D Semizarov
EAN: 9780470096048
COUNTRY: United States
PAGES:
WEIGHT: 839 g
HEIGHT: 236 cm
PUBLISHED BY: John Wiley & Sons Inc
DATE PUBLISHED: 2008-11-14
CITY:
GENRE: MEDICAL / Pharmacology
WIDTH: 160 cm
SPINE:
Book Themes:
Genetic engineering, Industrial chemistry and chemical engineering
?This book is highly recommended to active researchers in genomics and to the comparative and veterinary clinician or researchers looking for a focused review of the emerging discipline.? (The Veterinary Journal , August 2009) ?Overall, it provides excellent, up-to-date coverage of the application of genomics in drug development.? (Doody's Reviews, June 2009)
Dimitri Semizarov, PhD, is a Senior Group Leader in the Cancer Research Department of Abbott Laboratories' Global Pharmaceutical R&D. Dr. Semizarov leads cancer genomics research at Abbott, applying genomics technologies to enable personalization of cancer therapy. He is author or coauthor of more than twenty scientific articles and eight patent applications, as well as three book chapters (including two chapters in Wiley's Preclinical Development Handbook). Eric Blomme, DVM, PhD, Diplomate, American College of Veterinary Pathologists, is a Senior Project Leader for Cellular, Molecular, and Exploratory Toxicology in Global Pharmaceutical R&D at Abbott Laboratories. He has extensive drug discovery, toxicology, and screening experience working for Abbott, Pharmacia, Monsanto, Searle, Ohio State University, and Cornell University. Dr. Blomme has written over fifty journal articles and eight book chapters, and is a reviewer for multiple scientific journals in the fields of toxicology and pathology.